Evidence map›Paper›PMID 41390736›Full record

ArticleEpigenetics & chromatin2025

Gain of function p53 mutant R273H confers distinct methylation profiles and consequent YAP/TAZ signaling mediated activation of partial or full EMT states to colon tumours.

Harsha Rani, Seemadri Subhadarshini, Mohit Kumar Jolly, Vijayalakshmi Mahadevan

Abstract read
In one paragraph

Article in Epigenetics & chromatin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Harsha RaniInstitute of Bioinformatics and Applied Biotechnology (IBAB), Bangalore, India.
Seemadri SubhadarshiniDepartment of Bioengineering, Indian Institute of Science, Bangalore, India.
Mohit Kumar JollyDepartment of Bioengineering, Indian Institute of Science, Bangalore, India.
Vijayalakshmi MahadevanInstitute of Bioinformatics and Applied Biotechnology (IBAB), Bangalore, India. mviji@ibab.ac.in.

Funding

Indian Council of Medical Research 2020-5255/GENOMIC/ADHOC/BMSScience and Engineering Research Board CRG/2019/006509
6 · The paper itself

Abstract

backgroundMutations in tumour suppressor p53 are frequently implied in aggressive progression and metastasis in colorectal cancer. But the distinct phenotypes exhibited by site-specific mutations of p53 are not well elucidated. Here, we investigate the epigenetic and transcriptional impact of three major p53 hotspot mutations (R175H, R273H and R282W), through DNA methylation changes and single cell transcriptomics.

resultsWe observed that the p53 R273H mutation is associated with a partial epithelial-mesenchymal transition (pEMT) and increased metastatic progression. Analysis of DNA methylation patterns revealed a distinct epigenetic landscape in R273H-mutant tumours, with hypomethylated regions correlating with enhanced transcriptional activation of YAP/TAZ target genes thus promoting pEMT and EMT-like phenotype in CRC tumours. In vitro ChIP-seq experiments in colorectal cancer cells expressing the R273H mutant p53 (HT29) showed enrichment of mutant p53 at the promoters of YAP/TAZ target genes suggesting EMT/pEMT like states with R273H mutation. Further, simulations from a gene regulatory network incorporating the interactions of p53R273H with EMT regulators explain how this mutation shapes the phenotypic landscape accessible to cancer cells. Our analysis of single-cell transcriptomes of colorectal tumours reveals R273H-linked enrichment of partial and mesenchymal EMT phenotypes across tumour subpopulations in CRC.

conclusionsWe identified a distinct epigenetic signature associated with the p53 R273H mutation, characterised by hypomethylation of YAP/TAZ signalling genes that drives partial EMT and aggressive tumour behaviour. These findings highlight the importance of mutation-specific epigenetic regulation in shaping colorectal cancer progression and the need for developing therapeutic strategies tailored to p53 mutation status.

Indexed as

Adaptor Proteins, Signal TransducingColonic NeoplasmsDNA MethylationEpithelial-Mesenchymal TransitionGain of Function MutationPhosphoproteinsTranscription FactorsTumor Suppressor Protein p53Cell Line, TumorEpigenesis, GeneticGene Expression Regulation, NeoplasticHT29 CellsHumansSignal TransductionTrans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsAdaptor Proteins, Signal TransducingPhosphoproteinsTP53 protein, humanTrans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsTumor Suppressor Protein p53WWTR1 protein, humanYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID41390736
PMCPMC12822081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.